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There is an urgent need to develop new drugs for the treatment of tuberculosis, particularly against latent/
persistent forms of the causative agent, Mycobacterium tuberculosis. In this issue of Chemistry & Biology,
Krieger and colleagues use a structure-guided approach to develop novel inhibitors of malate synthase,
a target in the glyoxylate shunt that is critical for pathogen survival in chronic infection.Tuberculosis (TB) is one the ‘‘big-three’’
infectious diseases worldwide, killing
1–2 million people every year accord-
ing to the 2012 WHO Global Tuber-
culosis Report (http://www.who.int/tb/
publications/global_report/gtbr12_main.
pdf). Almost 9 million people suffer from
active disease, while another 2 billion (a
third of the world’s population) harbor
latent or persistent infection with Myco-
bacterium tuberculosis (Mtb), the bacte-
rium that causes TB. Current drug treat-
ments are prolonged and complicated,
and, to make matters even worse,
multiple or extensively drug-resistant
strains of Mtb (MDR-TB and XDR-TB,
respectively) are rapidly spreading. Thus,
there is an urgent need to develop new
drugs against novel targets, particularly
against latent/persistent forms of Mtb.
The glyoxylate shunt has received
attention as an important pathway in
Mtb, since it is upregulated to maintain
the tricarboxylic acid (TCA) cycle in the
absence of glycolysis during the persis-
tent phase of infection (McKinney et al.,
2000). A functional glyoxylate shunt has
recently been shown to be critical for es-
tablishing and maintaining Mtb infection
of macrophages and animal models (Mar-
rero et al., 2010). The glyoxylate shunt is
able to bypass the CO2-generating steps
of the TCA cycle, allowing synthesis of
oxaloacetate (and subsequent gluconeo-
genesis) under carbon-limiting conditions
(see Figure 1). This is accomplished by
utilizing two non-TCA enzymes: isocitrate
lyase (ICL), which hydrolyzes isocitrate
into glyoxylate and succinate, and malate
synthase (GlcB), which combines glyoxy-
late with acetyl-CoA to produce malate.
While the glyoxylate shunt is active in
most prokaryotes, lower eukaryotes, andplants, mammals appear to lack both en-
zymes in the pathway (Kondrashov et al.,
2006), making it even more attractive as
an antibacterial drug target. Examination
of the Mtb ICL and GlcB crystal structures
(Sharma et al., 2000; Smith et al., 2003)
suggested that the latter would provide
a more druggable target due to its deeper
and more hydrophobic active site.
In this issue of Chemistry & Biology,
Krieger et al. (2012) present a ‘‘textbook’’
example of structure-based drug design
to develop potent phenyl-diketo acid
(PKDA) inhibitors of malate synthase that
are active against a mouse model of TB.
To achieve this important milestone,
they harnessed an impressive array of
technologies, including structural biology,
medicinal chemistry, pharmacokinetics/
pharmacodynamics, and activity testing
using both whole-cell and mouse model
assays. They started by screening a
focused library of 35 glyoxylate-like
compounds for inhibition of GlcB activity
and found that 19 (all PKDAs) exhibited
activity. Substitution at the ortho-position
of the phenyl ring increased stability by
10-fold and improved the IC50, but further
attempts to stabilize the framework re-
sulted in loss of activity against GlcB. In
order to obtain co-crystals of GlcB with
the PKDA inhibitors, it proved necessary
to employ a Cys619Ala mutant of the Mtb
enzyme, which has a constricted entrance
to the active site channel. The co-crystals
revealed close contact between the
carboxylic acid of Asp633 and the face of
the PKDA aromatic ring via unusual
anion-p interactions. Based on the infor-
mation obtained from the inhibitor-bound
structures, a series of substitutions to the
PKDA framework were synthesized and
tested for activity, resulting in a consider-Chemistry & Biology 19, December 21, 2012 ªable body of structure-activity relation-
ship and modest improvement in activity.
Whole-cell testing of growth inhibition by
the PKDAs using Mtb grown on acetate-
supplemented M9 medium revealed
activity in the low micromolar range for
most compounds. Esterification of these
compounds to mask the acid lowered
the minimum inhibitory concentration
(MIC) by 8-fold, presumably by improv-
ing cellular uptake. When the most potent
inhibitor (Z-methyl 4-(2-chloro-6-fluoro-
3-methylphenyl)-2-hydroxy-4-oxobut-2-
enoate) was tested on a GlcB-overex-
pressing strain of Mtb, the MIC increased
by 8-fold after induction of GlcB expres-
sion, supporting on-target activity. The
compound above was selected for phar-
macokinetic, pharmacodynamic, and
toxicity studies in mice and was found to
be suitable for testing in the murine model
of acute TB infection. Dosing strategies
of 300–600 mg/kg once or twice daily
resulted in a significant (>100-fold) reduc-
tion in the Mtb load and inability to estab-
lish an acute infection.
Thus, this study has chemically vali-
dated the Mtb glyoxylate pathway (and
malate synthase, in particular) as a viable
new drug target and identified a lead
series of compounds (methyl esters of
PKDA) for further preclinical development.
It is particularly interesting to note that the
efficacy in the murine model of acute
infection was comparable to that of moxi-
floxacin, suggesting that GlcB is essential
for growth on carbon sources other than
fatty acids (although whole-cell activity of
the PKDA compounds was 4-fold higher
on acetate than dextrose). Obviously,
much more work remains to be done
before we can expect to see PKDA deriv-
atives in clinical use, but this report offers2012 Elsevier Ltd All rights reserved 1499
Figure 1. The Glyoxylate Cycle Bypasses the CO2-Generating Steps of the Citric Acid Cycle
Isocitrate lyase (ICL) and malate synthase (GlcB) shunt isocitrate (a TCA cycle intermediate) to malate via glyoxylate. This figure was modified from Wikipedia
(http://en.wikipedia.org/wiki/File:Glyoxylatepath.svg).
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novel chemotherapeutic agents to
combat the rising tide of MDR- and XDR-
TB. Given the presence of the glyoxylate
pathway in other pathogens and its
absence from humans, there must also
be hope for development of broad-spec-
trum antibiotics based on this target. It
should also be noted that much of this
work wasmade possible by the establish-
ment and success of the TB Structural
Genomics Consortium (TBsgc) (Chim
et al., 2011). Of the 1,523 structures in
the Protein Data Bank from Mycobacte-
rium, the TBsgc has submitted 245
(16%), while another 156 (10%) have
come from the Seattle Structural Geno-
mics Center for Infectious Disease. It is1500 Chemistry & Biology 19, December 21,heartening to see these large-scale efforts
beginning to bear fruit.
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